ALXA News Alert Alexza Pharmaceuticals (ALXA) 1.40 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alexza Pharmaceuticals (ALXA) 1.40 $ALXA

Alexza Amends Autoliv Agreement for Heat Packages Used in ADASUVE®
PR Newswire - Tue Dec 16, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that it amended its commercial Manufacturing and Supply Agreement ("Supply Agreement" with Autoliv ASP Inc., the North American subsidiary of Sweden-based Autoliv Inc. Autoliv manufactures chemical heat packages, a key component of Alexza's single-dose Staccato® system, including Alexza's commercial product ADASUVE (Staccato loxapine).
ALV: 106.19 (-0.42), ALXA: 1.40 (-0.05)

Diario Medico Names ADASUVE® in its "Best Ideas of 2014"
PR Newswire - Thu Dec 11, 9:00AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A. (Ferrer) announced today that the Spanish-based publication Diario Medico included ADASUVE® (Staccato® loxapine) in its "Best Ideas of 2014" awards. The Best Ideas awards by Diario Medico acknowledge the daily work of persons, institutions or enterprises that contributed to the improvement of medicine, healthcare, and public health during the previous year. Ferrer is Alexza's commercial partner for ADASUVE in the European Union, Latin America, and the Commonwealth of Independent States countries.
ALXA: 1.40 (-0.05)

Alexza Pharmaceuticals Announces Presentation at Stifel 2014 Healthcare Conference
PR Newswire - Thu Nov 06, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it is presenting at the Stifel 2014 Healthcare Conference, to be held November 18-19, 2014 at The New York Palace Hotel in New York.
ALXA: 1.40 (-0.05)

Midday Gainers/Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 11:47AM CST

SWIR: 47.29 (+0.13), PERI: 4.62 (-0.04), RMGN: 1.23 (+0.01), WWWW: 19.23 (-0.03), ASTI: 1.13 (-0.03), GNW: 8.40 (+0.01), SNMX: 5.95 (+0.34), ALXA: 1.40 (-0.05), PLUS: 72.63 (+0.09), PPO: 47.77 (unch), NSM: 28.77 (+1.59), AEZS: 0.59 (-0.02), WAC: 16.73 (-0.15), KATE: 29.83 (+0.44), CGG: 6.19 (-0.05), ANDE: 55.10 (+0.35), ENG: 1.80 (unch), PLNR: 7.04 (-0.15), ALG: 48.94 (-0.12), SZYM: 2.70 (+0.04)

Alexza continues down move after Q3 miss
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 10:57AM CST

ALXA: 1.40 (-0.05)

Alexza Pharmaceuticals' (ALXA) CEO Thomas King on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 9:17PM CST

ALXA: 1.40 (-0.05)

Alexza Pharmaceuticals (ALXA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:55PM CST

ALXA: 1.40 (-0.05)

Alexza Pharma misses by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:44PM CST

ALXA: 1.40 (-0.05)

Alexza Reports 2014 Third Quarter Financial Results
PR Newswire - Wed Nov 05, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended September 30, 2014. The net loss for the third quarter was $13.3 million compared to $12.4 million during the same quarter in 2013. The net loss for the nine months ended September 30, 2014 and 2013 was $30.0 million and $33.9 million, respectively. At September 30, 2014, Alexza had consolidated cash, cash equivalents, marketable securities, and restricted cash of $39.0 million.
ALXA: 1.40 (-0.05)

Global Panic Disorders Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gm823g/panic_disorders) has announced the addition of the "Panic Disorders Global Clinical Trials Review, H2, 2014" report to their offering. Panic Disorders Global Clinical Trials Review, H2, 2014" provides data on the Panic Disorders clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Panic Disorders. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Panic Disorders. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Pfizer Inc. - GlaxoSmithKline plc - ZonMw - Bluefish Pharmaceuticals AB - Teva Pharmaceutical Industries Limited - Alexza Pharmaceuticals, Inc. - Actavis plc - Abiogen Pharma S.p.A. Clinical Trial Overview of Top Institutes / Government - National Institute of Mental Health - Massachusetts General Hospital - The University of New South Wales - Charite - Universitatsmedizin Berlin - University of Pittsburgh - Samsung Medical Center - Maastricht University Medical Center - Karolinska Institute - Federal University of Rio de Janeiro - Maastricht University For more information visit http://www.researchandmarkets.com/research/gm..._disorders
PFE: 31.42 (-0.03), TEVA: 57.09 (+0.33), GSK: 42.85 (+0.11), ALXA: 1.40 (-0.05)

Market News: Apple Inc, Vitae Pharmaceuticals, Alexza Pharmaceuticals
at The Street - Mon Oct 27, 3:40PM CDT
Birinyi Associates president Laszlo Biriny opined that maybe the economy will catch up and the stock market may not have strong gains going forwardThe stock markets in the United States fluctuated on ...
VTAE: 19.20 (+0.02), AAPL: 112.01 (-0.53), ALXA: 1.40 (-0.05)

Alexza and Grupo Ferrer amend commercial partnership
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 9:25AM CDT

ALXA: 1.40 (-0.05)

Alexza and Ferrer Expand ADASUVE® Partnership
PR Newswire - Mon Oct 27, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A. (Ferrer) announced today that they have amended their agreement for ADASUVE® (Staccato® loxapine). Ferrer is Alexza's commercial partner for ADASUVE in the European Union, Latin America and the Commonwealth of Independent States countries (the Ferrer Territory). Ferrer and Alexza have agreed that Ferrer will purchase 2 million shares of Alexza common stock for $4.00 per share, thereby becoming the Company's largest shareholder. The purchase represents a combination of new investment and consideration for the elimination of certain future potential milestone payments under the agreement.
ALXA: 1.40 (-0.05)

Alexza Pharmaceuticals Provides Update on ADASUVE® U.S. Commercial Progress
PR Newswire - Thu Oct 09, 3:05PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on the U.S. commercial progress with ADASUVE® (loxapine) inhalation powder (Staccato® loxapine). Teva Pharmaceutical Industries Ltd. is Alexza's commercial partner for ADASUVE in the United States. Teva and Alexza announced the commencement of the U.S. launch of ADASUVE in March 2014.
TEVA: 57.09 (+0.33), ALXA: 1.40 (-0.05)

Alexza to Report 2014 Third Quarter Financial Results on Wednesday, November 5, 2014
PR Newswire - Wed Oct 08, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal quarter ended September 30, 2014 on Wednesday, November 5, 2014, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results.
ALXA: 1.40 (-0.05)

Alexza Pharmaceuticals and Ferrer Provide Update on ADASUVE® European Commercial Activities
PR Newswire - Thu Sep 18, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on the commercial activities related to ADASUVE® inhalation powder, pre-dispensed (Staccato® loxapine) in the European Union (EU). Grupo Ferrer Internacional, S.A. (Ferrer) is Alexza's commercial partner for ADASUVE in the European Union, Latin America and the CIS countries (the Ferrer Territory). Ferrer has distribution agreements with AOP Orphan Pharmaceuticals AG, Bioprojet, Galenica SA, and Medivir AB for some of the countries in Europe.
ALXA: 1.40 (-0.05)

INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Alexza Pharmaceuticals Inc. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Wed Sep 17, 1:18PM CDT
Levi & Korsinsky, LLP is investigating Alexza Pharmaceuticals Inc. (NasdaqGM: ALXA) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
ALXA: 1.40 (-0.05)

Why to Buy These 5 Under-$10 Stocks ASAP
at The Street - Wed Aug 20, 5:00AM CDT
Big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release.
BIRT: 6.60 (+0.02), EMKR: 5.30 (-0.03), CPST: 0.74 (+0.01), TGE: 2.11 (+0.15), ALXA: 1.40 (-0.05)

Alexza Pharmaceuticals Provides an Update on the Five Post-EMA Approval Studies for ADASUVE®
PR Newswire - Thu Aug 14, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on its European Medicines Agency (EMA) post-approval studies for ADASUVE® inhalation powder, pre-dispensed (loxapine). As part of the ADASUVE approval process with the EMA, Alexza is required to conduct five post-approval studies:
ALXA: 1.40 (-0.05)

Alexza Pharmaceuticals unveils ADASUVE in Guatemala for schizophrenia or bipolar disorder, reflecting ADASUVE 's first approval in a Latin American country
M2 - Mon Aug 11, 7:22AM CDT
Pharmaceutical company Alexza Pharmaceuticals (NasdaqGM:ALXA) on Friday announced the market availability of ADASUVE inhalation powder, pre-dispensed (loxapine) in Guatemala for treating schizophrenia or bipolar disorder, representing the first ADASUVE approval in Latin America.
ALXA: 1.40 (-0.05)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Pepsi Faces Georgia Labor Pressure Ahead of Strike

Updated Category News Views 121

A Pre-Dawn Labor Test Is Brewing in Georgia At 2:30 in the morning, nobody gathers outside a distribution center for the scenery. More than 100 Pepsi-Cola drivers from Atlanta and Lithonia are slated to meet Tuesday, November 24, at the Pepsi Distribution Center in Lithonia, Georgia, with Teamsters General President Sean M. O'Brien joining them. That hour matters. It puts...

Continue Reading
Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 60

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 149

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 83

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight

Updated Category News Views 87

Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Hoymiles Brings Plug-In Solar Flexibility to RE+ 2026

Updated Category News Views 105

A 1.8-kilogram box may not sound like much, but it captures where household solar is trying to go: smaller, less intimidating, and far easier to put to work. At RE+ 2026 in Las Vegas, Hoymiles laid out a residential lineup spanning plug-in solar, battery storage and conventional rooftop microinverters. This was not one flashy gadget looking for applause. It was a fairly...

Continue Reading

Top 5 Most Recently Viewed Articles

BearingPoint and Swish AI Join Forces to Elevate ITSM Solutions

Updated Category News Views 119

Transforming IT Service Management with AI As digital transformation accelerates, IT service teams encounter challenges like never before. To tackle these issues, management and technology consultancy BearingPoint has formed a significant partnership with Swish AI, a frontrunner in AI-driven IT Service Management (ITSM) solutions. Together, they aim to greatly improve...

Continue Reading
UAB Kvartalas Closes Subscription Early for Latest Bonds

Updated Category News Views 168

UAB Kvartalas Closes Subscription for 4th Tranche of Bonds UAB "Kvartalas", a legal entity committed to facilitating growth and innovation, has made a significant announcement regarding its bond issuance process. The company, registered with the legal code 305475438, has its headquarters situated at Jogailos St. 4, Vilnius, Republic of Lithuania. In response to...

Continue Reading
Transforming 620 Avenue of the Americas: A New Beginning

Updated Category News Views 97

RXR and Hudson Bay Capital Collaborate on a New Vision The partnership between RXR and Hudson Bay Capital marks an exciting chapter for 620 Avenue of the Americas, a renowned 500,000 square-foot property in the heart of the city. This iconic building is often viewed as a significant piece of real estate, known for its high ceilings and spacious floor plates, becoming a...

Continue Reading
Carolyn Mungo Takes Leadership Role at WFAA and KFAA

Updated Category News Views 230

Carolyn Mungo Takes Leadership Role at WFAA and KFAA TEGNA Inc. (NYSE: TGNA) has exciting news as Carolyn Mungo steps into the role of president and general manager at WFAA, the company’s ABC affiliate, along with KFAA, both serving the vibrant Dallas-Fort Worth area. This transition is effective immediately, marking a new chapter in Mungo's impressive career. A Proven...

Continue Reading
GeoPark Initiates Cash Tender Offer for Senior Notes Redemption

Updated Category News Views 157

GeoPark Starts Cash Tender Offer for Senior Notes GeoPark Limited, a prominent player in the oil and gas sector, has announced that it is launching a cash tender offer for all of its outstanding 5.500% Senior Notes due 2027. This strategic move is designed to improve the company’s capital structure and align its financial resources more effectively. The offering...

Continue Reading